ライフサイエンスコーパス: PPMS

1 PPMS prevalence (11.7%) and onset age (mean +/- standard

2 234 PPMS patients were identified from a population-based co

3 Using 2:1 randomization, 439 PPMS patients received two 1,000 mg intravenous rituxima

4 investigated cognitive and MRI change in 99 PPMS patients from five European centres for 2 years.

5 In addition, RRMS, SPMS, and PPMS were characterized by unique patterns of reactivity

6 ed to two other population- and clinic-based PPMS cohorts.

7 PMS: 64% fulfilled the criteria for definite PPMS, 35% for probable PPMS, and only 1% for possible PP

8 In definite PPMS, evidence of intrathecal synthesis of immunoglobuli

9 rosis (MS) have primary progressive disease (PPMS).

10 an be detected over a 1-year period in early PPMS.

11 eat shock proteins that were not observed in PPMS or SPMS.

12 an active inflammatory disease phenotype in PPMS patients.

13 nical presentation, and disease processes in PPMS could start decades prior to first apparent progres

14 ffect of rituximab on disease progression in PPMS appears to be marginal.

15 Disability progression in PPMS is variable and influenced by age at onset.

16 ebo-controlled OLYMPUS study of rituximab in PPMS, we found that the presence of CSF-restricted IgM O

17 edictive power models for clinical trials in PPMS.

18 ssociation between a common NR1H3 variant in PPMS patients and loss of function for the encoded prote

19 l fluid (CSF) and serum samples from a large PPMS patient cohort, and related to clinical and imaging

20 S), those developing primary-progressive MS (PPMS) scored a significant 4.6 to 6.9 IQ points lower th

21 ximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks.

22 ve MS [SPMS], and 40 primary progressive MS [PPMS]) from C1 to T10.

23 ion must be documented before a diagnosis of PPMS is made.) Three levels of diagnostic certainty have

24 aracteristics in the preprogressive phase of PPMS were indistinguishable from CIS/MS.

25 ating in a European natural history study of PPMS: 64% fulfilled the criteria for definite PPMS, 35%

26 F IgM OCB may be a biomarker for a subset of PPMS patients with more active inflammatory disease, who

27 1) in the RIS group were comparable to other PPMS populations (p > 0.05).

28 for probable PPMS, and only 1% for possible PPMS.

29 criteria for definite PPMS, 35% for probable PPMS, and only 1% for possible PPMS.

30 progressive (SPMS), and primary progressive (PPMS) MS from both healthy controls and other neurologic

31 s of primary progressive multiple sclerosis (PPMS) have shown significant changes in MR measures over

32 s of primary progressive multiple sclerosis (PPMS) pose particular diagnostic difficulties, both in e

33 s of primary progressive multiple sclerosis (PPMS), affecting both grey and white matter (GM and WM).

34 e to primary progressive multiple sclerosis (PPMS).

35 ial, progressive form of multiple sclerosis (PPMS).

36 n as primary-progressive multiple sclerosis (PPMS).

37 s in primary progressive multiple sclerosis (PPMS).

38 In the PPMS study, rituximab delayed time to confirmed disease

39 f subjects with RIS that evolved directly to PPMS were compared to those that developed a relapsing d

40 esions and being male predicted evolution to PPMS.

41 Subjects with RIS evolve to PPMS at the same frequency as expected from general MS p

42 Subjects who evolved to PPMS had more spinal cord lesions (100%) before symptoma

43 RIS evolved to PPMS more commonly in men (p = 0.005) and at an older ag

44 event consistent with CIS/MS, 15 evolved to PPMS).

45 Median time to PPMS was 3.5 years (range, 1.6-5.4).

46 h neuroaxonal degeneration seems to underlie PPMS, the pathogenesis and the extent to which immune-me

47 review of their considerable experience with PPMS.

48 f change within and between individuals with PPMS.

49 Forty-one patients with PPMS were followed prospectively for 5 years.

50 elapse-onset multiple sclerosis, people with PPMS are older at onset and a higher proportion are men.

51 Thirty-one subjects with PPMS within 5 years of symptom onset were studied at bas